PPLPHARMA Share Price Target 2026

CAGR-based price projection for Piramal Pharma Limited (PPLPHARMA) targeting 2026, derived from official NSE exchange closing prices.

Bear Case (14.2% CAGR)
Rs 226
2026 Target
Base Case (35.6% CAGR)
Rs 268
2026 Target
Bull Case (109.1% CAGR)
Rs 414
2026 Target

Current Market Snapshot

CMP: Rs 197.97
52W High: Rs 226.62
52W Low: Rs 145.98
1Y CAGR: 83.9%
3Y CAGR: 35.6%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 226 Rs 268 Rs 414

Other PPLPHARMA Price Targets

2025 2027 2028 2030 2035 2040 2050

Frequently Asked Questions

What is the PPLPHARMA share price target for 2026?

Based on historical growth analysis, the PPLPHARMA share price target for 2026 ranges from Rs 226 (conservative) to Rs 268 (base case) to Rs 414 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of PPLPHARMA?

The current market price of PPLPHARMA (Piramal Pharma Limited) is Rs 197.97. The 52-week high is Rs 226.62 and 52-week low is Rs 145.98.

Is PPLPHARMA a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for PPLPHARMA price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 14.2% CAGR), Base (35.6% CAGR), and Bull (optimistic at 109.1% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.